Boulder biotech firm Nivalis begins second phase of testing for cystic fibrosis drug

Daily Camera – Boulder biotech firm Nivalis Therapeutics (Nasdaq: NVLS) has begun the second phase of testing for a drug targeting cystic fibrosis, company officials said in a Tuesday press release. Keep reading.